|
Synonyms: Compound 424 [US11254674] | compound of formula (II) [WO2020190780] | FT-7051 | FT7051
Compound class:
Synthetic organic
Comment: Pocenbrodib (FT-7051) is an inhibitor that targets the bromodomains of the p300 (E1A-associated protein p300) and CBP (CREB binding protein) histone acetyltransferase enzymes [1,3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Pocenbrodib (FT-7051) was progressed as an anti-tumour clinical candidate. A phase 1 study in prostate cancer was terminated. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04575766 | A Study of FT-7051 in Men With MCRPC | Phase 1 Interventional | Novo Nordisk A/S | ||